Urodilatin: a new approach for the treatment of therapy-resistant acute renal failure after liver transplantation.
A pilot study was performed in patients after liver transplantation (Ltx) to examine the effect of continuous intravenous urodilatin (URO, CDD/ANP-95-126)-infusion as an alternative therapy of acute renal failure (ARF) resistant to conventional therapy. Eight patients who developed ARF after liver transplantation and fulfilled requirements for haemodialysis/haemofiltration were treated. After URO infusion was started, renal function improved and all patients developed a strong diuresis and natriuresis within 2-4 h. The extracellular expansion due to sodium and water retention in anuric/oliguric ARF lead to an increased central venous pressure (CVP) and elevated blood pressure. During the URO infusion CVP declined and systolic, as well as diastolic, blood pressure were stable. In six patients where haemodialysis/haemofiltration could be avoided, serum creatinine (SC) and blood urea nitrogen (BUN) declined during URO treatment and creatinine clearance (CC) also improved significantly. Fluid and electrolyte disturbances changed promptly and normalized. This was in concordance with renal excretion of electrolytes. Two patients still required haemodialysis/haemofiltration. The six patients who did not require haemodialysis/haemofiltration after URO treatment normalized concerning their renal function and did well in a control period of 12 weeks. The study shows that continuous low dose URO infusion may present a new concept for treatment of postoperative acute renal failure resistant to conventional therapy.
Cedidi
C
C
Niedersächsisches Institut für Peptid-Forschung (IPF), Medizinischen Hochschule Hannover, Germany.
Meyer
M
M
Kuse
E R
ER
Schulz-Knappe
P
P
Ringe
B
B
Frei
U
U
Pichlmayr
R
R
Forssmann
W G
WG
D058186:Acute Kidney Injury / Q000188:drug therapy*; D000328:Adult; D009320:Atrial Natriuretic Factor / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use*; D005260:Female; D017583:Hemodiafiltration; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D010865:Pilot Projects
D004232:Diuretics; D010446:Peptide Fragments; C056452:Ularitide; D009320:Atrial Natriuretic Factor